Retatrutide + Cagrilintide

What Is the Retatrutide and Cagrilintide Combination?

Retatrutide is an investigational peptide built to activate three separate hormone receptors at once, GLP-1, GIP, and glucagon, giving it one of the broadest mechanisms among current metabolic peptides. Cagrilintide, on the other hand, is a long-acting analog of amylin, a hormone released alongside insulin that signals fullness through a receptor system entirely separate from the GLP-1 family.

Because these two peptides work through non-overlapping hormone systems, one from the incretin and glucagon family, the other from the amylin family, researchers have shown particular interest in combining them, building on the precedent set by cagrilintide's pairing with semaglutide (branded as CagriSema) in pharmaceutical development.

What This Combination is Being Researched For?

• Body Weight Through Two Separate Mechanisms

  Retatrutide's own Phase 2 trial data reported some of the largest weight reductions seen in this drug class, driven by its triple-receptor mechanism.^[1] Cagrilintide's research separately ties its weight effects to amylin receptor activation in the brain.^[2]

• Appetite Signaling From Two Angles

  Retatrutide affects appetite through GLP-1 and GIP receptor activity, while Cagrilintide affects it through an entirely separate amylin receptor pathway, giving researchers interest in whether combining them produces a more complete appetite-suppressing signal than either alone.

• Precedent From Similar Combinations

  Interest in this specific pairing builds on the established combination of cagrilintide with semaglutide, a GLP-1-only compound, which has shown that pairing an amylin analog with an incretin-based peptide can produce effects beyond what either compound achieves individually.

How the Combination Works

• Retatrutide's Triple-Receptor Mechanism

  Research points to retatrutide activating the GLP-1, GIP, and glucagon receptors simultaneously, combining effects on insulin release, appetite signaling, and energy expenditure through the added glucagon receptor component.^[1]

• Cagrilintide's Amylin Receptor Mechanism

  Research points to Cagrilintide binding amylin receptors in the brain, particularly subtypes AMY1R and AMY3R, involved in processing signals related to fullness and food intake, a mechanism entirely distinct from the incretin pathway retatrutide targets.^[2]

• Why the Two Are Paired

  Since retatrutide's mechanism centers on gut and pancreatic hormone receptors while Cagrilintide's centers on amylin signaling in the brain, researchers combining them are generally interested in whether addressing both systems at once produces a more complete metabolic signal than either pathway alone.

Reconstitution and Handling

Both peptides are typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out for each peptide separately before mixing. Keel Bio's calculator is a commonly used tool for this. Once reconstituted, both solutions are kept refrigerated to help preserve stability.

Key Takeaways

Retatrutide and Cagrilintide are paired because they represent two of the broadest and most distinct mechanisms in current metabolic peptide research: one activating three separate incretin-family receptors, the other activating an entirely separate amylin pathway. The rationale for combining them builds on real precedent, cagrilintide's established pairing with semaglutide, but no published data exists for this specific combination. Both remain investigational, with retatrutide in Phase 3 trials and Cagrilintide most developed in its combination with semaglutide rather than as a standalone approved product.

Frequently Asked Questions

Sources and Research

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
2. Carvas AO, Leuthardt A, Kulka P, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine. 2025;118:105836.